How to Decide Between Class I, II, III Medical Device Registration in China: Guide

1. Introduction: Why Classification Matters

Every foreign medical device company that wants to sell in China must first answer a single question that determines the entire trajectory of its market-entry strategy: What NMPA classification does my device fall under? Get this wrong, and your application will almost certainly be rejected or returned for re-filing — wasting anywhere from six to eighteen months and sinking RMB 100,000 to well over RMB 1,000,000 in sunk costs before you ever submit a single validated dossier.[1]

China’s National Medical Products Administration (NMPA, formerly CFDA) regulates all medical devices sold within the People’s Republic under Decree 739 (Regulations on the Supervision and Administration of Medical Devices, effective 2021). This regulation, together with the accompanying Classification Rules (NMPA Decree No. 15 series), divides devices into three risk-based classes. The class you land on dictates your registration route, your clinical evidence requirements, your timeline, your cost, and your post-market obligations.

This guide is designed to give foreign manufacturers, regulatory affairs professionals, and China-market strategists a decision-oriented framework for determining their device’s correct NMPA class. We will walk through the three-class system, compare it with EU MDR and FDA frameworks, provide a detailed decision checklist, and offer practical guidance on what to do if you disagree with NMPA’s preliminary determination.

2. The Three-Classification System

China’s medical device classification system is structurally similar to the Global Harmonization Task Force (GHTF) model but has important national variations that foreign companies often overlook.

2.1 Class I (Low Risk)

Class I devices present minimal risk to the human body. They are typically non-invasive, do not require sterilization, and have transient or no contact with the body. Examples include examination gloves, elastic bandages, manual surgical instruments, and tongue depressors. Registration is handled at the provincial NMPA office via a notification (filing) process rather than a full review. No clinical trial is required, and the process typically takes 3–6 months.

2.2 Class II (Medium Risk)

Class II devices pose moderate risk. They may be invasive (but not surgically implanted), have short- to medium-term contact with the body, or incorporate active diagnostic functionality. Examples include ECG monitors, ultrasound diagnostic equipment, infusion pumps, and most sterile surgical instruments. Registration is handled directly by NMPA in Beijing and requires a clinical evaluation that may include a clinical trial. The typical timeline is 8–14 months, and cost is significantly higher than Class I.

2.3 Class III (High Risk)

Class III devices sustain or support life, are implanted in the body, or present a high potential risk of illness or injury. Examples include pacemakers, coronary stents, orthopedic implants, ventilators, and HIV diagnostic reagents. Registration is handled by NMPA’s Center for Medical Device Evaluation (CMDE) and almost always requires a full clinical trial conducted in China or recognized overseas. The timeline ranges from 18–36 months and costs can run into the millions of renminbi.

2.4 How NMPA Differs from EU MDR and FDA

Foreign companies familiar with the EU MDR classification (Annex VIII) or the U.S. FDA three-tier system (Class I/II/III) should be aware of some key differences:

• Rule-based, not pre-market precedent-based (vs. FDA): The FDA classes devices largely by pre-existing classification (product code, 510(k) predicate). NMPA applies a rule-based matrix (14 classification rules) that evaluates each device on its intrinsic characteristics, regardless of foreign precedent. A device that is Class II in the U.S. may be Class III in China.
• Stricter on duration of contact (vs. EU MDR): NMPA’s Classification Rules place greater weight on contact duration with the body. Transient contact (<60 minutes), short-term (<30 days), and long-term (>30 days) are hard thresholds that frequently push a device into a higher class than it would receive under EU MDR Rule 4–6 equivalents.
• Active devices are treated conservatively: Any device that delivers energy to the body (electrical, mechanical, thermal) is upward-classified more aggressively than under EU MDR. An active diagnostic device that is Class IIa under MDR may be Class III under NMPA if it is used to monitor vital physiological parameters.

A detailed side-by-side comparison is available in our related article NMPA vs. FDA vs. EU MDR: A Classification Comparison.

3. Detailed Comparison: Class I vs. Class II vs. Class III

The table below provides benchmark data across the dimensions that matter most for planning your China registration strategy. All figures are based on 2024–2026 averages and are indicative; actual outcomes depend on device complexity, completeness of the submitted dossier, and current CMDE workload.

These benchmarks underscore a critical strategic point: the classification decision has massive downstream consequences for budget, staffing, and go-to-market timing. A misclassification that pushes a device from Class II to Class III can add a year or more of clinical trial time and over RMB 1 million in extra costs.

4. Classification Decision Framework

How do you actually determine which class applies to your device? The following step-by-step framework follows the NMPA Classification Rules (Decree No. 15 series, 2021 revision) and the GB/T 16886 series (biological evaluation of medical devices). We recommend working through this framework with a regulatory affairs specialist who has direct experience with NMPA submissions.

Step 1: Define Intended Use

NMPA evaluates the intended use as the primary classification determinant. Write a single-sentence intended use statement exactly as it will appear on your product labelling. A change of even one word (e.g., “for diagnostic use” vs. “for monitoring”) can shift the class. Ask yourself: Is the device intended for diagnosis, treatment, monitoring, mitigation, or prevention of disease? Does it support or sustain life?

Step 2: Determine Invasiveness Level

NMPA recognizes three invasiveness categories:

• Non-invasive: No contact with the body (e.g., in vitro diagnostic instruments, hospital furniture) or contact only with intact skin.
• Invasive via body orifice: Enters the body through a natural opening but does not penetrate internal surfaces (e.g., endoscopes, catheters).
• Surgically invasive: Penetrates the skin or internal body surfaces (e.g., implants, surgical instruments, needles).

Step 3: Measure Duration of Contact

NMPA uses three hard thresholds that directly influence class:

• Transient: Less than 60 minutes of cumulative contact.
• Short-term: 60 minutes to 30 days of continuous or cumulative contact.
• Long-term: More than 30 days of continuous or cumulative contact.

Each step up in duration pushes the device at least one class higher. For example, a non-invasive device with transient contact is Class I; with short-term contact it can be Class II; with long-term contact it is likely Class III.

Step 4: Determine Active vs. Non-Active

If the device relies on electrical or other energy sources (not including energy generated by the body or gravity), it is an active device. Active devices are generally classified one level higher than their passive equivalents. NMPA applies additional sub-rules for active therapeutic devices (Rule 5–6), active diagnostic devices (Rule 7–9), and active devices that administer or remove medicines or body fluids (Rule 10).

Step 5: Apply the Specific Rules

NMPA’s Classification Rules contain 14 numbered rules covering non-invasive devices (Rules 1–4), invasive devices (Rules 5–5B), active devices (Rules 6–9), and special devices (Rules 10–14). Each rule combines the factors above to produce a final class. For instance, Rule 1 states: “Non-invasive devices that do not contact injured skin and are not intended for long-term use are Class I, except those that modify the biological or chemical composition of body fluids or are connected to an active medical device.”

Step 6: Conduct a GB/T 16886 Biological Evaluation

For any invasive device, NMPA requires evidence that the device is biocompatible in accordance with the GB/T 16886 series (which mirrors ISO 10993). The biological evaluation can affect classification if the device releases substances into the body or is intended for implantation. In borderline cases, a failed biocompatibility assessment can push a device from Class II to Class III.

5. Classification Examples: Real Products in Each Class

The following table provides 12 representative product examples with their NMPA classification, along with a brief explanation of the decision rationale. Use this as a reference when evaluating your own device.

As the table shows, the line between Class II and Class III is frequently crossed when a device is implantable, life-supporting, or diagnostic for high-risk pathogens. If your product falls into any of these categories, assume Class III until proven otherwise.

6. Challenging a Classification

What should you do if NMPA’s preliminary classification differs from your own assessment? The regulations provide a formal reclassification mechanism, but it must be used strategically.

6.1 The Reclassification Request Process

If you disagree with the classification assigned by NMPA (for example, during a preliminary consultation or after receiving a deficiency notice), you can submit a reclassification request to CMDE. The request must include:

• A detailed statement of your proposed classification and the rationale.
• Specific reference to the relevant Classification Rule (Rules 1–14) and your argument for why that rule supports your proposed class.
• Comparative analysis with similar products already classified in the NMPA Catalog.
• Supporting evidence (e.g., intended use labelling, biocompatibility data, clinical data if relevant).

6.2 Timeline and Success Rate

Reclassification requests typically take 3–6 months to process. The success rate for well-substantiated requests is estimated at approximately 40–50% based on industry reports.[2] The key success factors are (a) citing an identical or near-identical product already classified in the NMPA Catalog, and (b) demonstrating that the device’s clinical risk profile is aligned with the lower class.

6.3 When Not to Challenge

Reclassification is not advisable when:

• The device is clearly implantable (Rule 5B almost always yields Class III).
• The device is an active life-support device (Rule 6).
• The device is an in vitro diagnostic for a high-risk infectious disease (Rule 14).
• The cost and time of the reclassification process (3–6 months, RMB 50,000–100,000 plus consulting fees) would exceed the savings from a lower class.

In many cases, accepting the higher classification and planning for the corresponding timeline and budget is more efficient than fighting a reclassification battle that may not succeed.

7. Common Reclassification Triggers

Even after you obtain your registration certificate, your device’s classification is not permanently fixed. The following changes can trigger a re-evaluation by NMPA and possibly a new registration under a different class. Being aware of these triggers can help you avoid compliance surprises.

7.1 Software Updates

China has adopted increasingly stringent rules for medical device software (SaMD). Under the Guidelines on the Classification of Standalone Medical Device Software (2023 revision), software updates that add new clinical indications, change the algorithm to affect clinical decision-making, or alter the severity of the condition being diagnosed can push a software product from Class II to Class III. Foreign SaMD companies should classify conservatively from the start, as a mid-life reclassification can require withdrawing the product from the market until the new registration is complete.[3]

7.2 New Intended Uses

Adding a new intended use — for example, taking a device initially cleared for monitoring and extending it to diagnosis — almost always triggers a reclassification review. NMPA treats any change in intended use as a “substantial change” requiring a new registration application, and the classification is re-evaluated from scratch.

7.3 Material Changes

Changing the material of a device that contacts the body (e.g., switching from medical-grade stainless steel to a polymer, or changing the coating on an implant) can trigger reclassification if the new material has not been previously evaluated under that class. The biological evaluation under GB/T 16886 may reveal different risk characteristics that warrant a higher class.

7.4 Manufacturing Process Changes

NMPA considers changes in the sterilization method (e.g., from ethylene oxide to gamma irradiation) or the addition of a sterile claim to a previously non-sterile device as potential reclassification triggers. Sterile devices are almost always at least Class II.

7.5 Post-Market Adverse Events

If post-market surveillance reveals a pattern of serious adverse events that suggests the device’s risk profile is higher than originally classified, NMPA may initiate a reclassification on its own authority. This is rare but has occurred for certain implantable devices and active therapeutic devices.

Quick-Reference Classification Decision Checklist

Use this ordered checklist when evaluating any medical device for NMPA registration. Each step moves you closer to a defensible classification determination.

1. Write your intended use statement in a single sentence. Be precise — this is the foundation of your classification argument.
2. Determine invasiveness: Is the device non-invasive, invasive through an orifice, or surgically invasive?
3. Measure contact duration: Transient (<60 min), short-term (<30 days), or long-term (>30 days)?
4. Identify the energy source: Is the device active (powered) or non-active? If active, what is its therapeutic or diagnostic function?
5. Apply the 14 Classification Rules in order: start with Rule 1 and proceed until one definitively assigns a class.
6. Cross-check against the NMPA Classification Catalog for similar products with an already-assigned class.
7. Conduct a preliminary biological evaluation (GB/T 16886) for any invasive device to identify factors that could upward-classify.
8. Document your rationale in a classification memorandum that you can submit to NMPA or to a notifying body if challenged.
9. If uncertain, request a preliminary consultation with CMDE’s classification division (“Classification Consultation Service”) before filing your official application.
10. Re-check annually: Review any changes to your device (software, materials, intended use) that could trigger reclassification.

Following this checklist systematically is the single most effective way to avoid a rejected application or a costly reclassification mid-way through the registration process.

Where to Go From Here

Determining your device’s correct NMPA classification is the critical first step, but it is far from the only one. Once you have a clear classification, your next steps depend on the class you have identified. The following resources from china-gateway360.com will guide you through the rest of the registration journey:

• Complete Guide to Class II Medical Device Registration in China — A step-by-step walkthrough of the dossier submission, clinical evaluation, QMS audit, and timeline management for Class II devices.
• Class III Medical Device Clinical Trials in China: A Practical Guide — Everything you need to know about designing and conducting an NMPA-acceptable clinical trial, including multi-center trial requirements and acceptance of overseas data.
• Medical Device Registration Cost Calculator for China — An interactive tool that estimates your total registration cost (filing fees, testing, clinical trial, consulting, and MAH maintenance) based on your device class, complexity, and existing conformity documentation.

In addition, we recommend the following actions:

• Engage a China-based regulatory consultant who has submitted devices in your class within the past 12 months. NMPA’s requirements evolve rapidly, and up-to-date experience is invaluable.
• Download the NMPA Classification Catalog (in Chinese) and search for your product type. Even if your English-language team cannot read the catalog directly, a translator or consultant can run keyword searches that reveal the class of similar products.
• Monitor NMPA’s draft regulation page for proposed changes to the Classification Rules. As of mid-2026, NMPA has signalled a potential revision to the rules governing AI-based diagnostic software and combination products (drug-device and biologic-device combinations).

For a comprehensive overview of the entire NMPA medical device registration process, start with our flagship guide: NMPA Medical Device Registration: The Complete 2026 Overview.

How to Decide Between Class I, II, III Medical Device Registration in China: Guide — first published on China Gateway 360. Last updated: July 2026.